MoFo BioMeter - Volume 2, Issue 2: May 2013 - Flat BioMeter Value and Decline in Deal Volume are Hallmarks of Q1

more+
less-

The Morrison & Foerster BioMeter for the first quarter of 2013 shows a flat quarter for BioMeter value and a decline in dealmaking activity. A small number of large deals dominate an otherwise quiet quarter.

In the first quarter of 2013, the average BioMeter value for all transactions was approximately $60 million, a significant increase compared to the same quarter in 2012. Much of this value is attributable to two transactions, however, the BMS/Reckitt transaction for multiple OTC products in Latin America, and the AstraZeneca/Moderna transaction for mRNA technology. Excluding these two transactions, the BioMeter value for the first quarter was $16.3 million, a slight decline from the same quarter in 2012.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Topics:  Biotechnology, OTC, Pharmaceutical, Prescription Drugs, Valuation

Published In: General Business Updates, International Trade Updates, Science, Computers & Technology Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© MoFo Tech | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »